Sanofi Pasteur Presents Positive Results of Tetravalent Dengue Candidate Vaccine
These results have prompted Sanofi Pasteur to immediately expand ongoingclinical trials in Asia and Latin America. Submission to health authoritiesfor registration is anticipated in 2012.
"Sanofi Pasteur made research for a vaccine against dengue fever one ofits top priorities by investing in the most promising technology anddedicating top scientists to this lifesaving project," said Wayne Pisano,President and Chief Executive Officer of Sanofi Pasteur. "Sanofi Pasteur'sgoal is to make dengue fever a vaccine-preventable disease as quickly aspossible with a vaccine available to people living in endemic countries ortraveling to tropical destinations."
Immunization with Sanofi Pasteur's tetravalent dengue candidate vaccinegenerated a sero-neutralizing antibody response against all four serotypes ofthe virus responsible for dengue fever in 100 percent of adults whoparticipated in a trial in the United States.(1)
"Developing a dengue vaccine has been a major challenge for over adecade, and we are very pleased with the breakthrough progress made by SanofiPasteur with its tetravalent dengue vaccine," said Harold Margolis, MD,Director of the Pediatric Dengue Vaccine Initiative (PDVI). "We believe thismoves the world closer to a dengue vaccine that will be available for peoplewho most need it."
Dengue fever is a mosquito-borne disease affecting up to 100 millionpeople each year and resulting in 24,000 deaths, mostly among children,according to estimates from the World Health Organization (WHO).(2),(3)Overall, the disease is a potential threat for close to half the world'spopulation. Dengue disease if often cyclical and causes spikes in demand onlocal medical resources and places tremendous pressure on strained hospitalsand clinics located in endemic countries.
Dengue fever occurs mostly in tropical and subtropical countries and itis spreading to new parts of the globe each year. For example, outbreaksrecently have been observed in Paraguay and the Middle East. In addition,dengue affects countries such as Australia (Queensland) and the United States(Puerto Rico, Texas-Mexico border, Hawaii and the US-affiliated PacificIslands). A substantial number of people traveling to endemic regions arealso infected each year.
Sanofi Pasteur's tetravalent dengue candidate vaccine is based on a newtechnology incorporating the protein envelopes that provide immunity againstthe four virus types responsible for dengue fever and the most severe formsof the disease-dengue hemorrhagic fever and dengue shock syndrome.
Sanofi-aventis, a leading global pharmaceutical company, discovers,develops and distributes therapeutic solutions to improve the lives ofeveryone. Sanofi-aventis is listed in Paris (EURONEXT : SAN) and in New York(NYSE : SNY).
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, providedmore than a billion doses of vaccine in 2006, making it possible to immunizemore than 500 million people across the globe. A world leader in the vaccineindustry, Sanofi Pasteur offers the broadest range of vaccines protectingagainst 20 infectious diseases. The company's heritage, to create vaccinesthat protect life, dates back more than a century. Sanofi Pasteur is thelargest company entirely dedicated to vaccines. Every day, the companyinvests more than EUR1 million in research and development. For moreinformation, please visit: www.sanofipasteur.com orhttp://www.sanofipasteur.us
You May Also Like